CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Axumin PET/CTdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03373006
NCT03373006Phase 2Completed
CompareCT.gov

A Phase II Study to Evaluate Axumin PET/CT for Risk Stratification for Laser Focal Therapy of Intermediate Risk Localized Prostate Cancer

HALO Diagnostics·interventional·Posted Dec 14, 2017·Updated May 25, 2022

In Brief

A Phase 2 clinical trial evaluating Axumin PET/CT for Prostate Cancer. Completed, enrolled 20 participants across 1 site.

Detailed Summary

To investigate the utility of fluciclovine F 18 for evaluation for metastatic disease in men undergoing laser focal therapy of prostate cancer and the impact on inclusion for a focal therapy cohort.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedDec 14, 2017
Enrollment StartFeb 27, 2018
Primary CompletionJan 30, 2020
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 8.5 years ago

Interventions

Axumin PET/CTdrug

Synthetic amino acid uptake agent injection followed by imaging